Grzegorz S Nowakowski MD

Hematologic Oncology

Assistant Professor, Internal Medicine, Mayo Medical School

200 1st St SwRochester, MN 55905
Phone+1 507-284-2511

Dr. Nowakowski is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nowakowski's full profile Already have an account?

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2002 - 2006
Zucker School of Medicine at Hofstra/Northwell at Norwalk HospitalResidency, Internal Medicine, 1999 - 2002
Medical University of WarsawClass of 1998

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MN State Medical License 2002 - 2027
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Centricity Patient Online, GE Healthcare, 2014-2017
CMS Meaningful Use Stage 1 Certification Centricity Enterprise (CE), GE Healthcare, 2014-2017
CMS Meaningful Use Stage 2 Certification Mayo Clinic Electronic Notes, Mayo Clinic, 2014-2017

Clinical Trials

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma Start of enrollment: 2008 Aug 25
COMPLETED
PHASE1, PHASE2
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
COMPLETED
PHASE1
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
ACTIVE_NOT_RECRUITING
PHASE2

Publications & Presentations

PubMed

Survival benefit of chemoradiotherapy in limited-stage mantle cell lymphoma: a National Cancer Database analysis.
Domitilla Baccon, Jihao Zhou, Suheil Albert Atallah-Yunes, Jacqueline F Wang, Steven R Hwang
Blood Neoplasia. 2026-11-01
EBV-Positive Sinonasal Plasma Cell Neoplasms: A Case Series With Favorable Outcomes in Elderly Males.
Izel Okcu, Husam A Jum'ah, Patrick B Johnston, David J Inwards, Suzanne R Hayman
Ejhaem. 2026-10-01
Clinical outcomes and safety of the immune checkpoint inhibitor rechallenge in Hodgkin lymphoma: an off-trial analysis.
Yoshito Nishimura, Joey Maiocco, Guneet Janda, Adrienne Nedved, Yiqun Han
Haematologica. 2026-09-24

Journal Articles

Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia
Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature

Abstracts/Posters

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients...
Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience
Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse
Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Friday Scientific Workshop on Innovation in Clinical Trials Design
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.
2019 ASCO Annual Meeting - 6/1/2019